Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 14/20 | 0.65 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.65 |
| ▸ | NQO2 | P16083 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131741 | 0.88 | PIN1 (0.54) | MTNR1AMTNR1BNQO2ALDH1A1CYP2D6 | |
| SCHEMBL9122419 | 0.84 | MTNR1A (0.61) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 | |
| SCHEMBL6217970 | 0.84 | MTNR1A (0.64) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 | |
| SCHEMBL4143654 | 0.84 | MTNR1A (0.64) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 | |
| Hydrochloric Acid SCHEMBL29669731 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 | |
| Hydrochloric Acid SCHEMBL20545631 | 0.83 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 | |
| SCHEMBL17785106 | 0.82 | MTNR1A (0.70) | MTNR1AMTNR1BNQO2ALDH1A1LMNA | |
| SCHEMBL8695136 | 0.82 | MTNR1A (0.67) | MTNR1AMTNR1BNQO2ALDH1A1LMNA | |
| SCHEMBL25029926 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2CYP2D6HTR6 | |
| SCHEMBL8033341 | 0.82 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2ALDH1A1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-17 | — | — | US | disclosed |
| US-12195478-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4487913-A2 | OPIOID RECEPTOR MODULATORS | The Trustees Of Columbia University In The City Of New York (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-3224261-B1 | OPIOID RECEPTOR MODULATORS | UNIV COLUMBIA (US) | 2024-09-18 | — | — | EP | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-11840541-B2 | Opioid receptor modulators | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | US | disclosed |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-23 | — | — | US | disclosed |
| EP-3224261-A1 | OPIOID RECEPTOR MODULATORS | The Trustees of Columbia University in the City of New York (US) | 2017-10-04 | — | — | EP | disclosed |
| WO-2016086158-A1 | OPIOID RECEPTOR MODULATORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-06-02 | — | — | WO | disclosed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7235569-B2 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH (US) | 2007-06-26 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | WYETH | 2005-01-06 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195478-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MTNR1A 233/4885MTNR1B 261/4885NQO2 2003/4885 |
| US-20170334923-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MTNR1A 245/4885MTNR1B 326/4885NQO2 1560/4885 |
| US-20250122213-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MTNR1A 233/4885MTNR1B 261/4885NQO2 2003/4885 |
| US-20230271976-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRL1, OPRD1 | MTNR1A 233/4885MTNR1B 261/4885NQO2 2003/4885 |
| US-20070225319-A1 | PIPERIDINYL INDOLE AND TETROHYDROPYRIDINYL INDOLE DERIVATIVES AND METHODS OF THEIR USE | TPH1, TPH2, HTR3A | MTNR1A 134/4885MTNR1B 119/4885NQO2 1180/4885 |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | MTNR1A 723/4885MTNR1B 592/4885NQO2 250/4885 |
| US-11840541-B2 | Opioid receptor modulators | OPRM1, OPRL1, OPRD1 | MTNR1A 245/4885MTNR1B 326/4885NQO2 1560/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | MTNR1A 723/4885MTNR1B 592/4885NQO2 250/4885 |
| US-20050004162-A1 | Piperidinyl indole and tetrohydropyridinyl indole derivatives and method of their use | TPH1, TPH2, HTR4 | MTNR1A 147/4885MTNR1B 129/4885NQO2 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.